Literature DB >> 32209447

DNA-PK, Nuclear mTOR, and the Androgen Pathway in Prostate Cancer.

Vincent Giguère1.   

Abstract

Androgen and its receptor (AR) are major drivers of prostate cancer (PCa), a leading cause of mortality in aging men. Thus, understanding the numerous mechanisms by which AR can promote the growth and proliferation of PCa cells and enable their escape from hormone-dependent therapies, eventually leading to metastasis and death of the patient, is essential to discover alternative therapeutic approaches. Recently, two structurally related members of the phosphatidylinositol 3-kinase-like protein kinase (PIKK) family, DNA-dependent protein kinase (DNA-PK) and mammalian target of rapamycin (mTOR), were shown to have a direct role in modulating AR activity on chromatin of PCa cells. In this review, the common features of DNA-PK and mTOR and the similarities in their noncanonical roles as transcription coregulators of the AR are highlighted. An outlook on how these findings could be translated into new approaches to manage and treat PCa is provided.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DNA repair; FOXA1; HOXB13; androgen receptor; coregulator; nuclear receptor; transcription

Mesh:

Substances:

Year:  2020        PMID: 32209447     DOI: 10.1016/j.trecan.2020.01.015

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  6 in total

1.  PROTAC Compounds Targeting Androgen Receptor for Cancer Therapeutics: Prostate Cancer and Kennedy's Disease.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2020-05-18       Impact factor: 4.345

Review 2.  Dual contribution of the mTOR pathway and of the metabolism of amino acids in prostate cancer.

Authors:  Alejandro Schcolnik-Cabrera; Daniel Juárez-López
Journal:  Cell Oncol (Dordr)       Date:  2022-08-29       Impact factor: 7.051

3.  Molecular regulation of lifespan extension in fertile ant workers.

Authors:  Matteo Antoine Negroni; Maide Nesibe Macit; Marah Stoldt; Barbara Feldmeyer; Susanne Foitzik
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2021-03-08       Impact factor: 6.237

4.  miR-145-5p Inhibits Neuroendocrine Differentiation and Tumor Growth by Regulating the SOX11/MYCN Axis in Prostate cancer.

Authors:  Shuya Ji; Yi Shi; Lin Yang; Feng Zhang; Yong Li; Feng Xu
Journal:  Front Genet       Date:  2022-03-09       Impact factor: 4.599

5.  Exploring the Pharmacological Mechanisms of Xihuang Pills Against Prostate Cancer via Integrating Network Pharmacology and Experimental Validation In Vitro and In Vivo.

Authors:  Yongrong Wu; Xujun You; Qunfang Lin; Wei Xiong; Yinmei Guo; Zhen Huang; Xinjun Dai; Zhengjia Chen; Si Mei; Yan Long; Xuefei Tian; Qing Zhou
Journal:  Front Pharmacol       Date:  2022-03-07       Impact factor: 5.810

Review 6.  Targeting Protein Kinases and Epigenetic Control as Combinatorial Therapy Options for Advanced Prostate Cancer Treatment.

Authors:  Soghra Bagheri; Mahdie Rahban; Fatemeh Bostanian; Fatemeh Esmaeilzadeh; Arash Bagherabadi; Samaneh Zolghadri; Agata Stanek
Journal:  Pharmaceutics       Date:  2022-02-25       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.